Loading stock data…
electroCore, Inc. (ECOR)
$9.08-0.13 (-1.41%)
Market ClosedLast close Sep 8
electroCore, Inc., a bioelectronic technology medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
electroCore, Inc. in the Healthcare sector is trading at $9.08 with a market capitalization of $82M. Wall Street consensus targets $19.17 (5 analysts), implying a +111.1% move over the next 12 months. The stock is currently 17% below its 52-week high of $10.95, remaining 32.0% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +111.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $9.58M↑ | $9.24M↑ | $8.69M↑ | $7.38M↑ | $6.72M |
| Gross Profit | $8.36M↑ | $8.17M↑ | $7.47M↑ | $6.44M↑ | $5.71M |
| Operating Income | -$5.32M↓ | -$2.94M↓ | -$2.88M↑ | -$3.51M↑ | -$3.82M |
| Net Income | -$5.27M↓ | -$3.04M↑ | -$3.40M↑ | -$3.67M↑ | -$3.85M |
Peer Comparison
JNJUNHPFE
Fundamentals
electroCore, Inc., a bioelectronic technology medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCor...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$81.80M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.68
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
270.43%
Volume
Today's trading volume
24,200
Recent News
electroCore Q2 Earnings Call Highlights
electroCore (NASDAQ:ECOR) reported second-quarter 2026 revenue of $9.5 million, up approximately 28% from $7.4 million a year earlier, as growth in Veterans Affairs prescription sales and direct-to-consumer Truvaga sales lifted results. The company raised its full-year revenue outlook to growth of m
electroCore, Inc. (ECOR) Reports Q2 Loss, Tops Revenue Estimates
electroCore (ECOR) delivered earnings and revenue surprises of +19.51% and +0.92%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Rigel Pharmaceuticals (RIGL) Q2 Earnings Miss Estimates
Rigel (RIGL) delivered earnings and revenue surprises of -3.30% and +14.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
electroCore Touts 30% Growth Outlook, VA Opportunity at LD Micro Conference
electroCore (NASDAQ:ECOR) Interim President and CFO Joshua Lev said the bioelectronic technology company is focused on expanding its non-invasive vagus nerve stimulation platform across federal health care, commercial insurance channels and consumer wellness markets. Speaking at the LD Micro event,
electroCore (ECOR) Q1 2026 Earnings Transcript
Thomas Errico: Good afternoon, everyone, and thank you for joining electroCore, Inc.'s first quarter 2026 earnings call. This is the first earnings call since we announced our leadership transition, and I want to take a moment to share how encouraged I am by the progress we have made executing that transition and by the momentum we continue to see across the organization. At the same time, Michael Fox joined us as chief operating officer on April 13, bringing more than 35 years of commercial leadership experience across complex healthcare markets, including extensive work within the federal systems and the U.S. Department of Veteran Affairs.